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Although many therapeutic modalities have been
tested on alopecia areata, patient outcomes have been
disappointing. Use of animal models would help to de-
velop more e⁄cient therapies as well as understanding
therapeutic mechanisms. We have demonstrated that
0.1% topical anthralin ointment is 100% e¡ective in re-
storing follicular activity in Dundee experimental bald-
ing rats. This is the most promising topical treatment
for Dundee experimental balding rats among the ther-
apeutic agents tested on this model. Various cytokines
have been shown to be associated with the pathogenesis
of alopecia areata. To test whether any of these cyto-
kines might be modulated by anthralin, an RNase
protection assay and the real-time polymerase chain
reaction were performed to compare their expression
between anthralin-treated and control skins. These ex-
periments showed that expression of tumor necrosis
factor-a and interferon-c was inhibited by anthralin,
whereas expression of interleukin-1a/b and their recep-
tor antagonist, interleukin-1Ra, and interleukin-10 was
stimulated by anthralin. In addition, using an antibody-
based multi-immunoblotting technique, we found that
certain signaling regulatory proteins were modulated
by anthralin. Their potential roles in reversing the
autoimmune-arrested follicular activity in Dundee
experimental balding rats are discussed. Key words:
autoimmunity/hair follicles/protein kinases. JID Symposium
Proceedings 8:87 ^90, 2003
A
wide range of treatments has been tried on alopecia
areata (AA) patients, including contact sensitizers,
immunomodulators, and biologic response modi-
¢ers (Rokhsar et al, 1998; Shapiro and Price, 1998).
Unfortunately, none of the therapeutic modalities
produces consistently successful results, and many have untoward
side-e¡ects. Topical anthralin treatment of AA was found to be
e¡ective on patients by some investigators (Fiedler-Weiss and
Buys, 1987), but not by others (Nelson and Spielvogel, 1985). An-
imal models provide a means whereby new forms of treatment
can be tested and the underlying mechanisms can be studied
more extensively. One of two rodent models for AA is the Dun-
dee experimental bald rat (DEBR), a subpopulation of the inbred
rat strain, which exhibits hair loss lesions similar to that which is
observed in human AA (Michie et al, 1991; Zhang and Oliver,
1994). All DEBR rats develop a normal coat of hair from birth
up to 4 mo. Then, up to 30% of males and 80% of females start
to lose hair on their heads and then typically progress to the
£anks and the entire body (Michie et al, 1991). Several reports have
demonstrated that the DEBR rat is a useful model to study drug
e¡ects on AA, including cyclosporine A, FK506, and le£unomide
(Cao et al, submitted; Oliver and Lowe, 1995; McElwee et al, 1997,
unpublished data). In this paper, we discuss our recent ¢ndings
using DEBR rats and topical anthralin therapy as a model system
to study anthralin’s therapeutic e¡ects on restoring hair growth in
AA-a¡ected rats and the underlying molecular mechanisms that
may be responsible for its therapeutic action.
THERAPEUTIC EFFECTS OFANTHRALIN ON
RESTORING FOLLICULAR ACTIVITY IN DEBR RATS
Topical anthralin treatment was found to be e¡ective by other in-
vestigators for AA patients (Fiedler-Weiss and Buys, 1987). The
underlying molecular mechanisms are unknown. Recently, we
have found that topical treatment with 0.1% anthralin ointment
is 100% e¡ective on restoring the autoimmune-induced hair loss
in AA-a¡ected DEBR rats (Cao et al, submitted). Hair loss before
treatment ranged from small patches to entire body surfaces.
After 6^10 wk of anthralin treatment, follicular activity was re-
stored and hairs covered nearly all treated sides in all of the rats
tested, whereas the control sides remained bald (Cao et al, sub-
mitted). Topical anthralin appears to be the most promising ther-
apeutic agent to date tested on AA-a¡ected DEBR rats. Our
¢ndings demonstrate that the anthralin-treated DEBR rat is an
excellent model system to explore molecular mechanisms for
therapeutic actions on restoring follicular activity in AA.
MECHANISMS OFANTHRALIN’S THERAPEUTIC
ACTIONS
Anthralin remains one of the most e¡ective and most widely
used therapeutic agents for psoriasis (Gri⁄ths, 1998; Van de
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Kerkof et al, 1998; Smith and Lebwohl, 2000). Its anti-psoriatic
e⁄cacy may be related to the induction of cutaneous in£amma-
tion via the expression of cytokines and cell adhesion molecules,
including granulocyte-macrophage colony-stimulating factor,
interferon (IFN)-g, interleukin (IL)-6, IL-8, and tumor necrosis
factor (TNF)-a (Richter and Davies, 1995; Mrowietz et al, 1997;
Mˇller, 1997; Chodorowska, 1998; Lange et al, 1998).Whether any
of these cytokines is directly associated with anthralin’s anti-psor-
iatic actions is unclear. Little progress has been made in identify-
ing the molecular mechanisms of anthralin’s antipsoriatic actions
owing to a lack of relevant animal models for psoriasis.
The mechanism of anthralin’s therapeutic e¡ects in AA can
only be speculated. Anthralin is unstable when exposed to air
and the oxygen radicals generated from it are central to its anti-
in£ammatory and anti-proliferative e¡ects in psoriasis. In AA
therapy, free radicals generated from anthralin might be the me-
chanism of anti-in£ammatory action for clearing the in¢ltrated
lymphocytes. In this case, free radicals generated from anthralin
within the skin should selectively suppress in¢ltrated lympho-
cytes and leave the follicular cells unhindered in a¡ected skin;
however, our preliminary studies showed that lymphocytes and
di¡erent follicular cells were equally a¡ected by anthralin in vitro
(Fig 1), indicating that the mechanism is not simply a selective
cytotoxicity against lymphocytes. This was further supported by
the data of immunostaining using CD4 and CD8 antibodies
(Cao et al, submitted). Histologic examination revealed no reduc-
tion in the total number of in¢ltrated lymphocytes; however,
there was a general shift in the location of the CD8þ cells from
perifollicular and intrafollicular regions in untreated skin to a
uniform presence in the dermis upon successful anthralin treat-
ment. This pattern of CD8þ redistribution was consistent be-
tween all the rats tested. It would be interesting to study what
drives relocation of the CD8þ cells.
CYTOKINES MODULATED BYANTHRALIN IN
DEBR RATS
In skin, a large number of cytokines is produced under both nor-
mal and pathologic conditions, and these play important parts in
the pathogenesis of in£ammatory skin diseases. AA is believed to
be an autoimmune disease and a number of cytokines have been
indicated in its pathogenesis, including IL-1b,TNF-a, IFN-g, and
IL-1Ra (Ho¡mann et al, 1994; Cork et al, 1996; Philpott et al, 1996;
Carroll et al, 1997). As follicular activity in 15 AA-a¡ected DEBR
rats returned to near normal on all anthralin-treated sides,
whereas control sides remained unchanged, the underlying cellu-
lar and molecular changes mediated by anthralin must occur
locally within the treated skin. As anthralin does not exhibit a
selective cytotoxicity against lymphocytes, the modulatory e¡ects
of anthralin on the production of the various cytokines might be
the mechanism responsible for restoring follicular activity. Using
a RNase protection assay (RPA) and quantitative real-time poly-
merase chain reaction, we compared the expression of selected
cytokines in anthralin-treated and control DEBR rat skin.
Among the dozen cytokines tested, the expression of IL-1a/b,
IL-1Ra, and IL-10 were all consistently increased by anthralin
treatment using RPA, whereas IL-18 showed no signi¢cant
di¡erence (Table I). Other cytokines, including IL-2, IL-12,
TNF-a, granulocyte-macrophage colony-stimulating factor, and
IFN-g, were not detected consistently in the rat skin using RPA
assay. As TNF-a and IFN-g are two important cytokines that
might be associated with AA (Philpott et al, 1996; Carroll et al,
1997), a more sensitive assay, real-time polymerase chain reaction,
was used to test whether these two cytokines might be altered by
anthralin in AA-a¡ected rats. As shown in Table I, both IFN-g
and TNF-a demonstrated decreased expression after anthralin
treatment. Using the real-time polymerase chain reaction assay,
stimulation of IL-10, IL-1a, and IL-1Ra expression was con-
¢rmed. The expression of IL-1b and IL-1Ra modulation by
anthralin was also con¢rmed at a protein level by immuno-
histochemistry and western blotting (unpublished data).
It is not clear at present whether any of these cytokines play a
direct role in anthralin-induced hair regrowth in DEBR rats. The
correlation of TNF-a and IFN-g expression with anthralin’s e⁄-
cacy is intriguing, as suppression of these cytokines has been as-
sociated with improvement of various autoimmune conditions
(Cope, 1998; Feldmann and Maini, 2001). IL-10 and IL-1Ra have
been generally considered to be anti-in£ammatory cytokines and
their increased expression by anthralin might be responsible for
anthralin’s therapeutic action. The expression of IL-10 has also
been shown to be induced by diphenylcyclopropenone (DPCP)
therapy in AA patients (Ho¡mann et al, 1994). A similar experi-
ment was performed in our laboratory on another rodent model,
AA-a¡ected C3H/HeJ mice, and it was found that TNF-a expres-
sion was also reduced after anthralin treatment, using RPA (Tang
et al, submitted).
The increased expression of IL-1a/b by anthralin was a sur-
prise, as IL-1 has been shown to be associated with the pathogen-
esis of AA both in vivo and in vitro (Ho¡mann and Happle, 1995;
Philpott et al, 1996); however, there is also evidence indicating that
IL-1 can be a positive regulator of hair growth1 (Chedid et al,
1994). IL-1 is one of the primary cytokines induced by injury
and it is a primary stimulator of keratinocyte proliferation
and di¡erentiation during the early stages of wound healing
(Singer and Clark, 1999). More directly, IL-1 has been shown to
protect against chemotherapy-induced alopecia (Jimenez et al,
1991). It is not clear how upregulation of IL-1 correlates with
anthralin-induced hair regrowth in the AA-a¡ected DEBR
rats. Overexpression of IL-1 might be related to side-e¡ects of
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Figure1. Viability of di¡erent types of cells treated with anthralin
in vitro. Human peripheral blood mononuclear cells (Tcells), follicular ker-
atinocytes (FKC) and follicular dermal ¢broblasts (FDF) were treated with
di¡erent concentrations of anthralin for 72 h. Cell viability was determined
by MTT assay. All cell types showed a concentration-dependent reduction
in their viability and no di¡erences were observed between di¡erent cell
types.
Table I. Cytokines modulated by anthralin in DEBR rat skin
Cytokines Mean ratio (treated/control) P value Assay
IL-1a 2.68 0.0288 PCR
IL-1Ra 4.8 0.0015 PCR
IL-10 1.94 0.053 PCR
TNF-a 0.40 0.026 PCR
IFN-g 0.35 0.028 PCR
IL-1a 2.34 0.0014 RPA
IL-1b 5.53 o0.001 RPA
IL-1Ra 3.86 o0.001 RPA
IL-10 3.57 0.0012 RPA
IL-18 1.18 40.1 RPA
1Cairns JI, Cumpstone MB, KennedyAH, Harmon CS: Murine rIL-1a
stimulates proliferation and collagenase secretion by cultured hair follicles
from neonatal mice. J Invest Dermatol 92:410, 1989 (Abstr.)
88 TANG ETAL JID SYMPOSIUM PROCEEDINGS
in£ammation (dermatitis) caused by anthralin. At the same
time, its receptor antagonist, IL-1Ra, was also consistently in-
duced by anthralin. The end result might be determined by the
balance between IL-1a/b and IL-1Ra. The direct roles of IL-1
families in anthralin-induced hair growth in DEBR rats should
be investigated further.
SIGNALING PROTEINS MODULATED BYANTHRALIN
IN DEBR RATS
Many diseases result from malfunctions of intercellular and intra-
cellular signaling pathways, and small molecules blocking or
activating speci¢c pathways have been used to treat disease (Le-
vitzki, 1994, 1996). Although the e¡ects of various anti-in£amma-
tory drugs have been well studied in both animals and patients,
little is known about the signaling pathways involved in the ther-
apeutic responses. In£ammation and autoimmune conditions
trigger the activation of many transcriptional factors, such as c-
Jun and nuclear factor kB, via mitogen-activated protein
kinase pathways (extracellular signal-regulated kinase pathway,
c-Jun N-terminal kinase pathway, and p38 pathway), and the
IKB Kinase (IKK) complex (Hunter, 1995; Karin, 1999; Sampath
et al, 1999). Certain signal transduction pathways may represent
crucial molecular events in rat skin upon successful anthralin
therapy, and this has never been explored. Using an anti-
body-based multiprotein kinase expression analysis system called
KinetworksTM Protein Kinase Screen (KPKS) 1.0 developed by
Kinexus Bioinformatics Corporation (www.kinexus.ca), we
examined protein expression for 77 protein kinases in total cell
lysates pooled from 10 anthralin-treated and control skins.
The level of protein expression was analyzed using Bio-Rad’s
Fluor-STM Max Imager and quantitated using Bio-Rad’s software
QuantityOneTM (Bio-Rad, Hercules CA). A total of 53 di¡erent
protein kinases were detected in the DEBR rat skin. Those pro-
tein kinases with more than a 1.5-fold di¡erence between control
and anthralin-treated sites are listed in Table II. Several protein
kinases in the ERK pathway were downregulated at protein
levels. This was further con¢rmed using phospho-speci¢c antibo-
dies gainst the active forms of ERK1/2, which showed a
consistent reduction of ERK1/2 phosphorylation in anthralin-
treated sites (unpublished data). The implication of this ¢nding
in terms of anthralin’s therapeutic e¡ects is unclear and needs to
be investigated further. Although no obvious changes at the pro-
tein levels in the JNK pathway were observed, activation of
JNK2 and phosphorylation of c-June were dramatically in-
creased in anthralin-treated sites (unpublished data). Upregula-
tion of this pathway might presumably be due to the free
radicals generated by anthralin within the skin. Several isoforms
of PKC were stimulated by anthralin (Table II).Whereas this is
contradictory to the in vitro ¢ndings of Takahashi and Kamimura
(2001), it agrees with the in vivo ¢ndings of Li et al (1999). In addi-
tion, GSK-3 kinase expression and activity were decreased by an-
thralin. Its downstream substrate, b-catenin, and transcriptional
factor,TCF1 (Lef1), have been tightly linked to follicular activity
(Gat et al, 1998; Dasgupa and Fuchs, 1999). It would be important
to determine whether these downstream regulators are also
modulated in anthralin-treated DEBR rat skin. Other kinases
that are modulated by anthralin in DEBR rat skin include PKG,
LYN, JAK1, and CDC2 (Table II). These kinases are either im-
portant regulators of cell proliferation and di¡erentiation
(CDC2, PKG) or tightly linked to immune functions (LYN,
JAK1). Potentially, they can be highly relevant to follicular activ-
ity and cutaneous immune responses to anthralin.We are conti-
nuing to study signaling pathways modulated by anthralin in rat
skin and how they relate to the reversion of autoimmune-in-
duced arrest of follicular activity in AA-a¡ected rats.
CONCLUSIONS
Anthralin has been demonstrated to be the most e¡ective drug in
reversing autoimmune-induced arrest of follicles in AA-a¡ected
DEBR rats. There are many genes that can be modulated by an-
thralin in the skin.We have shown that downregulation of TNF-
a and IFN-g and upregulation of IL-10 and IL-1Ra may be
responsible for anthralin’s therapeutic e¡ects. We are currently
investigating cytokine expression at di¡erent time points after an-
thralin treatment and will use more advanced ‘‘postgenomic’’
technologies to search for other genes associated with anthralin’s
therapeutic e¡ects. At the protein level, it is clear that certain
signaling pathways involving various protein kinases and their
regulators and e¡ectors are modulated by anthralin. Further ex-
periments will be performed to clarify which particular signaling
pathways are directly linked to anthralin’s therapeutic actions.
Data obtained from classical single gene-based techniques is in-
triguing, but obtaining truly relevant in vivo genetic data regard-
ing therapeutic actions using more exploratory approaches is
di⁄cult because gene expression varies between individuals. Our
unilaterally treated DEBR rats with topical anthralin are excel-
lent model systems to study the in vivo therapeutic mechanisms
at molecular levels. We have demonstrated that the changes
mediated by anthralin between control and treated sides in the
same animal are quite consistent from animal to animal at both
mRNA and protein levels. These topically and unilaterally trea-
ted animal systems eliminate the potential problems associated
with variability between individuals when performing in vivo
gene expression analysis. In addition, the accessibility and visibi-
lity of skin and hair follicles will provide the convenience and
accuracy in correlating therapeutic e⁄cacy with molecular events.
Hopefully, in the near future, the newly developed exploratory
molecular approaches will bring us to the molecular ‘‘¢nger-
prints’’of anthralin’s action. Identi¢cation of one or more molecu-
lar pathways responsible for the anthralin-induced hair regrowth
in AA-a¡ected rats will o¡er new insights and new potential
treatment approaches to AA patients. The molecular events
mediated by anthralin might be common to other autoimmune
diseases and thus can potentially help in the design of more
rational therapies for other autoimmune disorders as well.
This work was supported by Canadian Dermatology Foundation and by the National
Alopecia Areata Foundation.
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